Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A New European Consortium to Boost our Understanding of IBD

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
A multi-modal integrated biomarker study Consortium to increase diagnostic precision in detection of the diseases.

The Inflammatory Bowel Disease Characterization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation.

The consortium associates 10 European partners from both academia and industry. It starts with a € 6M grant thanks to the European Commission´s 7th Framework Program (FP7).

The project will generate the largest collection of samples so far assembled from treatment naïve patients recently diagnosed with inflammatory bowel disease.

DNA methylation and RNA transcription status, protein markers, gut microbial content, patient genotype for known susceptibility loci and classical clinical data will be extensively analyzed for the characterization of the cohort in order to create a molecular snapshot of IBD in its early manifestation.

This massive molecular profiling will be used to yield a list of biomarkers indicative for onset of the disease.

The participating Small and Medium sized Enterprises (SMEs) will develop assays capable of analyzing panels of several hundred relevant protein markers as well as methods for rapid profiling of gut microbial content relevant for IBD.

The proposed biomarkers will form a solid ground for development of improved diagnostic assays and be a rich source to mine for novel therapeutic targets.

"We are pleased to have gathered such a strong combination of clinicians, clinical researchers, basic researchers and innovative SME:s into one focused project," said Dr. Mats Gullberg, project coordinator for IBD-Character and Chief Technology Officer at Olink Bioscience.

Dr. Gullberg continued, "The project will advance our understanding of IBD as well as generate proprietary products by the participating SMEs. The project will provide the most complete molecular characterization of samples from patients with IBD and also progress the field of analysis of large data sets containing different types of molecular markers from large sets of individuals."

Based on the findings within the IBD-Character project, results are expected to improve many aspects of patient care, including the development of new personalized medical strategies and treatments.

Consortium members

The project will be co-ordinated by Olink Bioscience (Sweden) with partners coming from several European countries including the United Kingdom, Sweden, Belgium, Spain and Norway.

The IBD-Character Consortium unites researchers from three SME:s, one research institute, five Universities and one public, non-profit organization.

IBD-Character is a four year project running from the 1st of December 2012 until the 30th of November 2016 and is funded by the 7th Framework Program of the European Commission. In addition to the research activities, IBD-Character will be organizing meetings, workshops and will be present at a number of international conferences.

Members of the consortium:
• Olink Bioscience (Coordinator, SME), Mats Gullberg, SE
• Diagenode (SME), Hélène Pendeville, BE
• Genetic Analsysis (SME), Heidi Vebø, NO
• Instituto Aragonés de Ciencias de la Salud/IIS Aragón, Fernando Gomollón, ES
• Linköpings Universitet, Johan Söderholm, Åsa Keita SE
• The University of Edinburgh, Jack Satsangi, UK
• Örebro University Hospital, Jonas Halfvarson, SE
• Centro Nacional de Análisis Genómico, Ivo Gut, Monica Bayés, ES
• Karolinska Institutet, Mauro D’Amato, SE
• Universitetet I Oslo, Morten H. Vatn, Bettina Kulle Andreassen, NO


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Olink Bioscience Appoints Sigma-Aldrich as Distributor of Duolink
Olink Bioscience will continue to develop the protein biomarker market.
Friday, May 17, 2013
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!